Neuphoria Therapeutics Inc.
NEUP
$4.12
-$0.25-5.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.09% | |||
| Cost of Revenue | -- | -425.12% | |||
| Gross Profit | -- | -60.84% | |||
| SG&A Expenses | -9.83% | 47.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.92% | 92.30% | |||
| Operating Income | 3.14% | -148.75% | |||
| Income Before Tax | -8.64% | -181.84% | |||
| Income Tax Expenses | 86.95% | -228.33% | |||
| Earnings from Continuing Operations | -11.51% | -178.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.51% | -178.88% | |||
| EBIT | 3.14% | -148.75% | |||
| EBITDA | 3.24% | -146.72% | |||
| EPS Basic | 5.60% | -171.32% | |||
| Normalized Basic EPS | 10.37% | -175.93% | |||
| EPS Diluted | 5.60% | -171.33% | |||
| Normalized Diluted EPS | 10.37% | -175.93% | |||
| Average Basic Shares Outstanding | 18.13% | 10.60% | |||
| Average Diluted Shares Outstanding | 18.13% | 10.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||